Merck will initially proffer $3 million for a license to Addex’ preclinical program, and firms will research other PAMs targeting the mGluR4. Addex and Merck & Co. entered a $170.5 million deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results